about
The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitisNanomedicine approaches for corneal diseasesDetection and prevention of ocular phototoxicity of ciprofloxacin and other fluoroquinolone antibioticsProteomic analysis of keratitis-associated Pseudomonas aeruginosa.Topical flagellin protects the injured corneas from Pseudomonas aeruginosa infection.Intravitreal administration of known phototoxicants in the rabbit fails to produce phototoxicity: implications for phototoxicity testing of intravitreally administered small molecule therapeutics.Corneal plaque containing levofloxacin in a dog.Sustained ocular delivery of ciprofloxacin using nanospheres and conventional contact lens materials.A drug-eluting contact lensToxicological considerations for intravitreal drugs.The role of besifloxacin in the treatment of bacterial conjunctivitis.Susceptibility of bacterial isolates to vancomycin and ceftazidime from patients with endophthalmitis: Is there a need to change the empirical therapy in suspected bacterial endophthalmitis?Comprehensive evaluation of formulation factors for ocular penetration of fluoroquinolones in rabbits using cassette dosing techniqueExperimental and computational characterization on the binding of two fluoroquinolones to bovine hemoglobin.Effect of norfloxacin and moxifloxacin on melanin synthesis and antioxidant enzymes activity in normal human melanocytes.Enhancement of lomefloxacin Hcl ocular efficacy via niosomal encapsulation: in vitro characterization and in vivo evaluation.Penetration of 0.3% ciprofloxacin, 0.3% ofloxacin, and 0.5% moxifloxacin into the cornea and aqueous humor of enucleated human eyesDevelopment of novel in silico model to predict corneal permeability for congeneric drugs: a QSPR approach.Probing the binding of two fluoroquinolones to lysozyme: a combined spectroscopic and docking study.Toxic interaction mechanism of two fluoroquinolones with serum albumin by spectroscopic and computational methods.Effect of fluoroquinolones on the expression of matrix metalloproteinase in debrided cornea of rats.Evaluation of Marbofloxacin in Beagle Dogs After Oral Dosing: Preclinical Safety Evaluation and Comparative Pharmacokinetics of Two Different Tablets.Common eye infections.
P2860
Q24631812-7FA17BAE-0DDB-4EBC-A02A-DCFA0371ABB2Q27022253-579E3C49-BEAA-4523-9407-20DE71E815D4Q34020997-1077F33F-2558-4697-B722-1A08F5EA48FDQ34127752-E35FFF12-5C55-40DB-901F-D3A12AA6A382Q35328441-87F3C59B-5CE9-4043-8F16-0647C17E4142Q35397051-0A1B13CE-8F2D-443F-89D0-0C357D3016B9Q35566243-116F7247-7F73-414E-B7D6-5982D4CCFF12Q35921444-F6A9F109-F49E-4BDA-A15D-1B8798793D82Q36311472-283894AD-814E-4242-972A-72B74088F4A8Q37882728-52A85307-79F8-4378-860E-6685C5693406Q38190827-26F0D500-6E7B-4324-9493-C27EA68CEE23Q38266641-4B375D33-1B4B-47C0-BE86-A100068D338BQ38651665-374876CB-8BB3-4523-A2B2-9805324492D1Q38728206-CA0A5038-5A5A-413F-94D5-4909B1EA32A4Q38936976-A2B96F6B-E4C6-4507-A4C8-CFF65438FFFFQ40653236-03F90CB8-1276-481F-BEFE-65E366FD59F3Q40969636-8A9B4ECE-4F4F-4128-8F75-0B2C6FFDF296Q42624533-9F973582-BB93-4AB0-8BE6-203A010AD7E8Q44740234-290101B3-6CB1-4487-8D08-BB23101561BBQ47647066-8F2ECB71-3D02-42A9-833D-960CC6480C58Q48313289-91901651-8759-4C83-9E53-1F51175EF88BQ54204498-AECD5C89-7F25-408A-A2BD-527154FB9E8FQ55322614-DFAE47BB-1A31-4C28-9330-950E9D399F20
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Ocular toxicity of fluoroquinolones.
@en
type
label
Ocular toxicity of fluoroquinolones.
@en
prefLabel
Ocular toxicity of fluoroquinolones.
@en
P2860
P1476
Ocular toxicity of fluoroquinolones.
@en
P2093
Andrew M Thompson
P2860
P304
P356
10.1111/J.1442-9071.2007.01552.X
P577
2007-08-01T00:00:00Z